CenterBook Partners LP Acquires 273,253 Shares of Syndax Pharmaceuticals, Inc. $SNDX

CenterBook Partners LP bought a new position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) in the third quarter, Holdings Channel.com reports. The fund bought 273,253 shares of the company’s stock, valued at approximately $5,137,000.

A number of other hedge funds have also bought and sold shares of SNDX. BlackRock Inc. bought a new stake in Syndax Pharmaceuticals during the second quarter valued at $197,177,000. Bank of America Corp DE bought a new position in shares of Syndax Pharmaceuticals in the 2nd quarter worth about $88,426,000. Elmind Capital LP bought a new position in shares of Syndax Pharmaceuticals in the 2nd quarter worth about $40,550,300. Trails Edge Capital Partners LP bought a new position in shares of Syndax Pharmaceuticals in the 2nd quarter worth about $24,264,600. Finally, Bank of New York Mellon Corp acquired a new position in shares of Syndax Pharmaceuticals in the 2nd quarter valued at about $22,736,000.

Key Syndax Pharmaceuticals News

Here are the key news stories impacting Syndax Pharmaceuticals this week:

• Positive Sentiment: Syndax expects 19 drug abstracts to be featured at ASH 2026, which may raise visibility for its oncology pipeline. The headlines do not disclose the data or establish whether the findings are favorable, so the abstracts are a potential catalyst rather than confirmed positive results. Article: Syndax Pharmaceuticals stock: ASH to feature 19 drug abstracts Article: Why Is Syndax Pharmaceuticals Drawing So Much ASH 2026 Attention?
• Neutral Sentiment: HC Wainwright reiterated a Buy rating and $36 price target. Its revisions were mixed: it slightly improved some 2026 and longer-term estimates, but reduced its 2027 and 2028 forecasts. Analyst estimates and rating
• Neutral Sentiment: A Seeking Alpha analysis says Revuforj is showing strong commercial growth, but identifies potential frontline AML use as a key factor for the company’s outlook. Article: Syndax Pharmaceuticals: Revuforj Shows Strong Commercial Growth, But Frontline AML Is The Key
• Negative Sentiment: Pomerantz LLP said it is investigating claims on behalf of Syndax investors. The announcement does not provide details of the claims, but the investigation adds legal uncertainty and may weigh on sentiment. Article: Pomerantz Law Firm Investigates Claims On Behalf of Syndax Investors

Insiders Place Their Bets

In related news, Director Dennis Podlesak sold 8,000 shares of the company’s stock in a transaction dated Thursday, October 29th. The shares were sold at an average price of $14.21, for a total value of $113,680.00. Following the sale, the director owned 239,763 shares in the company, valued at $3,407,032.23. This represents a 3.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 4.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on SNDX shares. Bank of America restated a “buy” rating on shares of Syndax Pharmaceuticals in a research report on Wednesday, August 5th. JPMorgan Chase & Co. lowered their target price on Syndax Pharmaceuticals from $44.00 to $40.00 and set an “overweight” rating for the company in a report on Tuesday, August 11th. Weiss Ratings upgraded Syndax Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday. Mizuho set a $43.00 price target on Syndax Pharmaceuticals in a research note on Tuesday. Finally, Jefferies Financial Group restated a “buy” rating and set a $35.00 price target on shares of Syndax Pharmaceuticals in a report on Tuesday, September 29th. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $41.60.

Syndax Pharmaceuticals Stock Up 1.8%

Shares of SNDX traded up $0.17 during trading hours on Friday, hitting $9.54. The stock had a trading volume of 4,170,993 shares, compared to its average volume of 2,850,792. Syndax Pharmaceuticals, Inc. has a 1-year low of $9.22 and a 1-year high of $25.59. The firm has a market capitalization of $845.34 million, a P/E ratio of -4.04 and a beta of 0.48. The firm has a 50 day simple moving average of $16.33 and a 200-day simple moving average of $20.02. The company has a debt-to-equity ratio of 38.95, a current ratio of 6.77 and a quick ratio of 6.44.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its earnings results on Monday, November 2nd. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.05). Syndax Pharmaceuticals had a negative return on equity of 517.88% and a negative net margin of 72.32%. The firm had revenue of $83.30 million for the quarter, compared to analyst estimates of $81.38 million. During the same period in the previous year, the company earned ($0.70) earnings per share. Syndax Pharmaceuticals’s revenue for the quarter was up 81.9% compared to the same quarter last year. Sell-side analysts predict that Syndax Pharmaceuticals, Inc. will post -2.08 EPS for the current fiscal year.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc (NASDAQ:SNDX) is a biopharmaceutical company focused on developing and commercializing therapies for cancer and immune-related diseases. Founded in 2005 and headquartered in Waltham, Massachusetts, the company develops medicines designed to address genetically defined cancers and serious complications associated with cancer treatment.

Syndax’s lead product is Revuforj (revumenib), an oral menin inhibitor approved in the United States for the treatment of relapsed or refractory acute leukemia with a KMT2A translocation in eligible adults and children.